CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies

In this phase I study, the investigators will first evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).

Study Overview

• Status: Active, not recruiting
• Conditions: B-cell Chronic Lymphocytic Leukemia; B-cell Non Hodgkin Lymphoma
• Intervention / Treatment: Biological: 0.75x10^6 cells/kg CAR20.19.22 cells; Biological: 1x10^6 cells/kg CAR20.19.22 cells; Biological: 2.5x10^6 cells/kg CAR20.19.22 cells; Biological: 5x10^6 cells/kg CAR20.19.22 cells; Biological: Dose expansion: The maximum tolerated dose of CAR20.19.22 cells

Detailed Description

This is a phase I, interventional, open label, dose-finding treatment study designed to evaluate the safety and efficacy CAR20.19.22 T-cells in adult patients with B-cell malignancies that have failed prior therapies.

• Study Type: Interventional
• Enrollment (Estimated): 48
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Medical College of Wisconsin Cancer Center Clinical Trials Office; Phone Number: 8900 1-866-680-0505; Email: cccto@mcw.edu

Study Locations

• United States
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Medical College of Wisconsin and Froedtert Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria for B-cell for non-Hodgkin lymphoma (NHL) and CLL (chronic lymphocytic leukemia) patients

1. Patients must be aged ≥18 years to 80 years with relapsed or refractory B-cell non-Hodgkin Lymphoma or chronic lymphocytic leukemia.
2. Absolute CD3 count ≥50 mm^3.
3. MRI brain and lumbar puncture with cerebrospinal fluid (CSF) analysis by cytology and flow cytometry without evidence of central nervous system (CNS) involvement ONLY in patients with history of CNS involvement or clinical suspicion at the time of enrollment.
4. Measurable disease must be documented within 4 weeks of apheresis date and is defined as nodal lesions >15 mm in the long axis or extranodal lesions >10 mm in long OR bone marrow involvement that is biopsy proven.
5. Karnofsky performance score ≥70.
6. Adequate hepatic function, defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase < 3x upper limit of normal (ULN); serum bilirubin < 2.0 mg/dL
7. ANC≥1000 with no G-CSF within 72 hours or pegylated G-CSF within 10 days unless bone marrow involvement is present.
8. Platelets ≥ 50,000 with no transfusion within 72 hours of eligibility testing unless bone marrow involvement is present.
9. Adequate renal function, defined as creatinine clearance≥60 ml/min AND serum Cr≤1.5 mg/dL.
10. Able to provide written informed consent.
11. Agree to practice birth control during the study.
12. Adequate cardiac function as indicated by New York Heart Association (NYHA) classification I or II AND left ventricular ejection fraction of ≥45% (by cardiac echocardiogram (ECHO) or MUGA) and adequate pulmonary function as indicated by room air oxygen saturation of ≥90%.
13. Expected survival >12 weeks.
14. Negative urine or serum pregnancy test in females of childbearing potential at study entry.
15. Meet criteria for regarding fertility and contraception detailed below.
16. No contraindication to central line access.
17. Diagnosis of CLL or B-cell NHL including follicular lymphoma, marginal zone lymphoma (splenic, nodal, extranodal), mantle cell lymphoma, Burkitt lymphoma, and DLBCL with associated subtypes (high-grade or aggressive B-cell lymphoma, T-cell/histocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, Epstein-Barr virus (EBV) + diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).
18. For CLL patients, must have active, measurable disease (>5% CLL involvement of marrow or nodal disease as noted above) and failed/progressed or been intolerant to both covalent Bruton's tyrosine kinase (BTK) inhibitors (ibrutinib, acalabruinitib, or zanabrutinib) and B-cell lymphoma 2 (BCL2) inhibitors (e.g., venetoclax).

19. For B-cell NHL patients must have active, measurable disease as defined in Inclusion criteria #4, relapsed or refractory disease within 12 months of their last lymphoma directed treatment. Additionally patient must meet, and meet the following criteria as applicable:

    1. Patients who relapsed within 12 months of autologous stem cell transplant or allogeneic stem cell transplant and have measurable disease are eligible.
    2. For patients who have not had a prior autologous/allogeneic transplant they must have received an anti-CD20 monoclonal antibody and at minimum two prior treatment regimens. ONE of the regimens must include a disease appropriate regimen as listed below:

    i. For large cell or Burkitt lymphoma: anthracycline containing treatment (e.g., rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone (R-CHOP), R-EPOCH, HyperCVAD, Pola-R-CHP, etc.).

ii. For follicular lymphoma: either prior bendamustine or anthracycline based therapy.

iii. For mantle cell lymphoma: either prior bendamustine, anthracycline based regimen, or cytarabine based therapy.

iv. For marginal zone lymphoma: prior bendamustine based therapy.

Exclusion Criteria for ALL patients.

1. Positive beta-human chorionic gonadotropin (HCG) in female of child-bearing potential.
2. Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.
3. History of significant autoimmune disease OR active, uncontrolled autoimmune phenomenon requiring steroid therapy defined as >20 mg of prednisone or equivalent daily.
4. Presence of ≥grade 3 non-hematologic toxicities as per CTCAE version 5.0 from any previous treatment unless it is felt to be due to underlying disease.
5. Concurrent use of investigational therapeutic agents or enrollment on another therapeutic clinical trial at any institution. Minimum of 14 days or 5 half-lives of the drug (whichever is shorter) washout prior to apheresis.
6. Refusal to participate in the long-term follow-up protocol.

7. Patients with active CNS involvement by malignancy on MRI or by lumbar puncture.

   a. Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was >4 weeks before enrollment and a remission documented within 8 weeks of planned CAR T-cell infusion by MRI brain and CSF analysis.

8. Previous recipients of allogeneic hematopoietic stem cell transplantation (AHCT) are excluded if they are <100 days' post-transplant, have evidence of active graft-versus-host-disease (GVHD) of any grade, or are currently on immunosuppression.
9. Anti-CD20 directed treatment within 4 weeks of cell infusion.
10. Anti-CD19 directed treatment within 4 weeks of cell infusion.
11. Anti-CD22 directed treatment within 4 weeks of cell infusion.

12. Cytotoxic chemotherapy, oral chemotherapeutic agents or antibody directed treatment within 14 days of lymphodepletion.

    1. Radiation is allowed to a single symptomatic site as long as other sites of measurable disease are present on eligibility scan.
    2. If patients receive steroids or any systemic disease targeting treatment, repeat scans are needed to confirm disease burden pre-lymphodepletion.

13. Cytotoxic chemotherapy, oral chemotherapeutic agents or antibody directed treatment within 14 days of apheresis.

    a. Corticosteroids are allowable up until 7 days prior to apheresis.

14. Patients post solid organ transplant who develop high grade lymphomas or leukemias.
15. Concurrent active malignancy other than basal or squamous cell carcinomas of the skin.
16. Prior CAR T-cell therapy (autologous or allogeneic) unless >90 days from prior CAR with repeat biopsy post-CAR demonstrating CD19 or CD20 expression of ≥20%.

Special Criteria for regarding Fertility and Contraception:

Female subjects of reproductive potential (women who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or have not undergone a sterilization procedure [hysterectomy or bilateral oophorectomy]) must have a negative serum or urine pregnancy test performed as part of eligibility criteria. Lactating women are eligible for this study but will be asked to not provide breast milk to their child from Day -4 through Day +90 after CAR T-cell therapy. It is possible they may no longer be able to lactate after receiving chemotherapy and treatment.

Due to the high-risk level of this study, while enrolled, all subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). Additionally, if participating in sexual activity that could lead to pregnancy, the study subject must agree to use reliable and double barrier methods of contraception during the follow-up period of the protocol.

Acceptable birth control includes a combination of two of the following methods:

• Condoms (male or female) with or without a spermicidal agent.
• Diaphragm or cervical cap with spermicide.
• Intrauterine device (IUD).
• Hormonal-based contraception.

Subjects who are not of reproductive potential (women who are premenarche or have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy tubal ligation, salpingectomy, and/or bilateral oophorectomy or men who have documented azoospermia) are eligible without requiring the use of contraception.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

10

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Indolent B-cell NHL Dose Level -2: 0.75x10^6 cells/kg: CAR20.19.22; The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.	Biological: 0.75x10^6 cells/kg CAR20.19.22 cells; Dose escalation: CAR20.19.22 cells will be administered at one of three dose levels either fresh or thawed after cryopreservation by IV injection. Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6.
Experimental: Indolent B-cell NHL Dose Level -1: 1x10^6 cells/kg: CAR20.19.22; The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.	Biological: 1x10^6 cells/kg CAR20.19.22 cells; CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection. Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6.
Experimental: Indolent B-cell NHL Dose Level 0: 2.5x10^6 cells/kg: CAR20.19.22; The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.	Biological: 2.5x10^6 cells/kg CAR20.19.22 cells; CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection. The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6.
Experimental: Indolent B-cell NHL Dose Level 1: 5x10^6 cells/kg: CAR20.19.22; The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.	Biological: 5x10^6 cells/kg CAR20.19.22 cells; CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection. The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6.
Experimental: Indolent B-cell NHL Dose Expansion: CAR20.19.22; The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6 cells/kg.	Biological: Dose expansion: The maximum tolerated dose of CAR20.19.22 cells; Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6 cells/kg.
Experimental: Aggressive B-cell NHL Dose Level -1: .75x10^6 cells/kg: CAR20.19.22; The investigators will start at a dose of 1x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.	Biological: 0.75x10^6 cells/kg CAR20.19.22 cells; Dose escalation: CAR20.19.22 cells will be administered at one of three dose levels either fresh or thawed after cryopreservation by IV injection. Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6.
Experimental: Aggressive B-cell NHL Dose Level 0: 1x10^6 cells/kg: CAR20.19.22; The investigators will start at a dose of 1x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.	Biological: 1x10^6 cells/kg CAR20.19.22 cells; CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection. Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6.
Experimental: Aggressive B-cell NHL Dose Level 1: 2.5x10^6 cells/kg: CAR20.19.22; The investigators will start at a dose of 1x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.	Biological: 2.5x10^6 cells/kg CAR20.19.22 cells; CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection. The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6.
Experimental: Aggressive B-cell NHL Dose Level 2: 5x10^6 cells/kg: CAR20.19.22; The investigators will start at a dose of 1.0x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.	Biological: 5x10^6 cells/kg CAR20.19.22 cells; CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection. The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6.
Experimental: Aggressive B-cell NHL Dose Expansion: CAR20.19.22; The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6 cells/kg.	Biological: Dose expansion: The maximum tolerated dose of CAR20.19.22 cells; Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6 cells/kg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Non-hematologic Adverse Events after Infusion	Occurrence of adverse events will be defined as non-hematologic Grade 3/4 toxicity grade per NCI CTCAE version 5.0.	28 days after infusion
Number of grade 3-4 cytokine release syndrome (CRS).	Grade 3-4 CRS as graded per the recent Transplant and Cell Therapy (TCT) consensus criteria.	28 days after infusion
Number of grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS)	Grade 3-4 ICANS as graded per the recent Transplant and Cell Therapy (TCT) consensus criteria.	28 days after infusion

Collaborators and Investigators

• Sponsor: Medical College of Wisconsin
• Collaborators: Miltenyi Biomedicine GmbH
• Investigators: Principal Investigator: Nirav Shah, MD, Medical College of Wisconsin

Study record dates

Study Major Dates

• Study Start (Actual): June 30, 2022
• Primary Completion (Estimated): February 1, 2025
• Study Completion (Estimated): February 1, 2026

Study Registration Dates

• First Submitted: October 17, 2021
• First Submitted That Met QC Criteria: October 17, 2021
• First Posted (Actual): October 26, 2021

Study Record Updates

• Last Update Posted (Actual): August 23, 2023
• Last Update Submitted That Met QC Criteria: August 21, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: CAR-T; B-cell Chronic Lymphocytic Leukemia; Chimeric antigen receptor T-cell therapy; CAR Therapy; B-cell antigens; B-cell Non Hodgkin Lymphoma
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease Attributes; Leukemia; Leukemia, B-Cell; Lymphoma; Chronic Disease; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid
• Other Study ID Numbers: PRO00041528

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No